DUBLIN, Ireland — Horizon Pharma plc plans to acquire Crealta Holdings LLC for $510 million in cash.

Horizon said the deal will bring the company Krystexxa (pegloticase), the first and only Food and Drug Administration-approved drug for chronic refractory gout.

“The Crealta acquisition further diversifies our portfolio of medicines and aligns with our focus of acquiring value-enhancing, clinically differentiated, long-life medicines that treat orphan diseases,” Timothy Walbert, chairman, president and chief executive officer of Horizon, stated in announcing the acquisition on Friday. “We have a proven track record of strong commercial execution and the ability to generate volume growth for clinically differentiated medicines. With our experienced rheumatology sales force and orphan expertise, we expect to expand the number of patients identified and treated with Krystexxa. As with all of our orphan medicines, we plan to maximize additional development opportunities of Krystexxa.”

Chronic refractory gout is a type of arthritis that occurs when uric acid build up in the blood remains high and inflammation persists even after treatment with conventional therapies. The disease affects an estimated 50,000 people in the United States.

A biologic medicine, Krystexxa is indicated for adults who have tried or cannot take oral gout medications and still have high uric acid levels and signs and symptoms of gout. Between 4,000 and 5,000 patients have been treated with Krystexxa since its FDA approval in 2010.

The acquisition transaction has been approved by the boards of both companies and, pending customary closing conditions and regulatory approvals, is expected close in the first quarter of 2016.